搜索
 >  免疫检查点蛋白>B7-2 >CD6-C52H5

Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, His Tag (HPLC-verified)

分子别名(Synonym)

CD86,B7-2,B70,CD28LG2,LAB72,MGC34413

表达区间及表达系统(Source)

Cynomolgus / Rhesus macaque B7-2, His Tag (HPLC-verified) (CD6-C52H5) is expressed from human 293 cells (HEK293). It contains AA Ala 19 - His 240 (Accession # G7NXR4-1). In the region Ala 19 - His 240, the AA sequence of Cynomolgus and Rhesus macaque B7-2 are homologus.

Predicted N-terminus: Ala 19

蛋白结构(Molecular Characterization)

Online(Ala 19 - His 240) G7NXR4-1

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 27.3 kDa. The protein migrates as 50-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

>95% as determined by SEC-HPLC.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Cynomolgus / Rhesus macaque B7-2, His Tag (HPLC-verified) (Cat. No. CD6-C52H5) SDS-PAGE gel

Cynomolgus / Rhesus macaque B7-2, His Tag (HPLC-verified) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-HPLC

Cynomolgus / Rhesus macaque B7-2, His Tag (HPLC-verified) (Cat. No. CD6-C52H5) HPLC images

The purity of Cynomolgus / Rhesus macaque B7-2, His Tag (HPLC-verified) (Cat. No. CD6-C52H5) was more than 95% as determined by SEC-HPLC.

 

活性(Bioactivity)-ELISA

Biotinylated Human ELISA

Immobilized Cynomolgus / Rhesus macaque CTLA-4, Fc Tag (Cat. No. CT4-C5256) at 5 μg/mL (100 μL/well) can bind Cynomolgus / Rhesus macaque B7-2, His Tag (HPLC-verified) (Cat. No. CD6-C52H5) with a linear range of 0.312-5 μg/mL (QC tested).

Protocol

Biotinylated Human  ELISA

Immobilized Cynomolgus / Rhesus macaque B7-2, His Tag (HPLC-verified) (Cat. No. CD6-C52H5) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) with a linear range of 0.02-0.625 μg/mL (Routinely tested).

Protocol

背景(Background)

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

 

前沿进展

 
货号/价格

CD6-C52H5-100ug / ¥2600

CD6-C52H5-1mg / ¥16500

开发建议
文档
联系电话:
400-682-2521(全国)
010-57737274(北京)
021-26136428(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
techsupport@acrobiosystems.com
B7-2靶点信息
英文全称:Cluster of Differentiation 86
中文全称:分化群86
种类:Homo sapiens
上市药物数量:2详情
临床药物数量:9详情
最高研发阶段:批准上市
查看更多信息

消息提示

请输入您的联系方式,再点击提交!

确定